An interim analyses of the phase 3 “ASCEND” clinical trial evaluating single-agent Calquence (acalabrutinib) compared to Rituxan (rituximab) plus idelasib or bendamustine in recurrent chronic lymphocytic leukemia (CLL) is closed early due to favorable results. (1) About chronic lymphocytic leukemia CLL is the most common type of leukemia in adults. (2) with an average age... Continue Reading →
Combining the kinase inhibitor Imbruvica (ibrutinib) with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center (ACC). The team will present the results from its pilot study …
Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Chronic lymphocytic leukemia is the most common form of adult leukemia. The American … Continue reading "Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia"
The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not received prior therapy, or whose CLL has stopped responding to prior therapies. CLL is a type of cancer … Continue reading "Arzerra® Approved as Maintenance Therapy for Advanced CLL"